Table 1 Clinical characteristics from the University of East Anglia, UK (UEA), GU Biobank at UHN, Canada (UHN), Trinity College at Dublin, Ireland (Dublin)
From: A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer
Patient clinical characteristics | UEA | UHN | Dublin |
|---|---|---|---|
n (%) | 194 (48) | 155 (38) | 59 (14) |
Benign | 109 (56) | 46 (30) | 27 (46) |
PCa | 85 (44) | 109 (70) | 32 (54) |
Gleason score | |||
6 | 17 (20) | 64 (59) | 15 (47) |
7 | 42 (49) | 32 (29) | 9 (28) |
8–10 | 26 (31) | 13 (12) | 8 (25) |
Clinical T stage | |||
T1 | 38 (45) | 91 (83) | 20 (63) |
T2 | 14 (16) | 16 (15) | 11 (34) |
T3 | 19 (22) | 2 (2) | 1 (3) |
T4 | 14 (16) | 0 | 0 |
% Biopsy cores positive for PCa | |||
Median | 57% | 20% | 21% |
Range | 7–100% | 5–100% | 6–100% |
Interquartile range | 33%–100% | 9%–38% | 13%–43% |
N/A | 9 | 1 | 0 |
Age at enrollment | |||
Median | 67 | 64 | 65 |
Range | 42–85 | 37–83 | 46–80 |
Interquartile range | 62–73 | 57–69 | 58–71 |
PSA at presentation | |||
Median | 8.4 | 5.8 | 5.9 |
Range | 0.2–277.3 | 0.01–67.31 | 0.5–248 |
Interquartile range | 5.8–12.2 | 3.97–9.07 | 3.85–8.64 |
Prostate volume | |||
Median | 59.54 | 47 | |
Range | 21.08–244.6 | 16.05–127.0 | |
Interquartile range | 42.52–86.52 | 34–57 | |
N/A | 92 | 18 | 59 |
Perineural invasion | |||
Yes | 28 | 11 | 4 |
No | 80 | 17 | 55 |
N/A | 86 | 127 | 0 |
CAPRA risk | |||
CAPRA low | 10 (12) | 57 (52) | 13 (41) |
CAPRA intermediate | 32 (38) | 36 (33) | 14 (44) |
CAPRA high | 43 (51) | 16 (15) | 5 (16) |
D’Amico risk | |||
D’Amico low | 8 (9) | 52 (48) | 9 (28) |
D’Amico intermediate | 29 (34) | 39 (36) | 13 (41) |
D’Amico high | 48 (56) | 18 (17) | 10 (31) |